106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2021 All rights reserved
ASCONSCLC311213a
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/thoracic-cancer-guidelines.
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
thoracic-cancer-guidelines. Copyright © 2021 by American Society of Clinical Oncolog y.
All rights reserved.
Source
Daly ME, Singh N, Ismaila N, et al. Management of Stage III NSCLC: ASCO Guideline.
J Clin Oncol. 2021 Dec 22. doi:10.1200/JCO.21.02528
Abbreviations
CT, computed tomography; EGFR, epidermal growth factor receptor; FDG PET,
fluorodeoxyglucose-positron emission tomography; Gy, Gray; NSCLC, non-small cell
lung cancer; PD-L1, programmed death-ligand 1
